Iqvia 3Q Profit, Rev Rise on Higher Demand

Dow Jones

Oct 28

By Rob Curran

Iqvia's third-quarter net income and revenue rose amid growing demand for its healthcare technology and research services.

The Research Triangle Park, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted third-quarter earnings of $331 million, or $1.93 a share, up from $285 million, or $1.55 a share, a year earlier.

Stripping out certain one-off items, IQVIA logged adjusted earnings of $3 a share, edging the average Wall Street estimate of $2.98 a share, as per FactSet.

Revenue rose 5.2% to $4.1 billion, about in line with the average analyst forecast of $4.08 billion, according to FactSet. Research-and-development revenue rose 4.5% to $2.26 billion.

IQVIA now anticipates 2025 adjusted earnings in a range between $11.85 and $11.95 a share, compared with a previous estimate of $11.75 to $12.05 a share.

IQVIA now expects 2025 revenue of $16.15 billion to $16.25 billion.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

October 28, 2025 07:50 ET (11:50 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2578956596"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2578956596\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2578956596?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 19:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2578956596","market":"fut","top_or_hot":-1,"title":"Iqvia 3Q Profit, Rev Rise on Higher Demand","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Iqvia's third-quarter net income and revenue rose amid growing demand for its healthcare technology and research services. \n</p>\n<p>\n  The Research Triangle Park, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted third-quarter earnings of $331 million, or $1.93 a share, up from $285 million, or $1.55 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-off items, IQVIA logged adjusted earnings of $3 a share, edging the average Wall Street estimate of $2.98 a share, as per FactSet. \n</p>\n<p>\n  Revenue rose 5.2% to $4.1 billion, about in line with the average analyst forecast of $4.08 billion, according to FactSet. Research-and-development revenue rose 4.5% to $2.26 billion. \n</p>\n<p>\n  IQVIA now anticipates 2025 adjusted earnings in a range between $11.85 and $11.95 a share, compared with a previous estimate of $11.75 to $12.05 a share. \n</p>\n<p>\n  IQVIA now expects 2025 revenue of $16.15 billion to $16.25 billion. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2025 07:50 ET (11:50 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Iqvia 3Q Profit, Rev Rise on Higher Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIqvia 3Q Profit, Rev Rise on Higher Demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-28 19:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Iqvia's third-quarter net income and revenue rose amid growing demand for its healthcare technology and research services. \n</p>\n<p>\n  The Research Triangle Park, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted third-quarter earnings of $331 million, or $1.93 a share, up from $285 million, or $1.55 a share, a year earlier. \n</p>\n<p>\n  Stripping out certain one-off items, IQVIA logged adjusted earnings of $3 a share, edging the average Wall Street estimate of $2.98 a share, as per FactSet. \n</p>\n<p>\n  Revenue rose 5.2% to $4.1 billion, about in line with the average analyst forecast of $4.08 billion, according to FactSet. Research-and-development revenue rose 4.5% to $2.26 billion. \n</p>\n<p>\n  IQVIA now anticipates 2025 adjusted earnings in a range between $11.85 and $11.95 a share, compared with a previous estimate of $11.75 to $12.05 a share. \n</p>\n<p>\n  IQVIA now expects 2025 revenue of $16.15 billion to $16.25 billion. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2025 07:50 ET (11:50 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1989764664.SGD","symbol_name":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2578956596","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2578956596","pubTimestamp":1761652200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Iqvia's third-quarter net income and revenue rose amid growing demand for its healthcare technology and research services.The Research Triangle Park, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted third-quarter earnings of $331 million, or $1.93 a share, up from $285 million, or $1.55 a share, a year earlier.Stripping out certain one-off items, IQVIA logged adjusted earnings of $3 a share, edging the average Wall Street estimate of $2.98 a share, as per FactSet.Revenue rose 5.2% to $4.1 billion, about in line with the average analyst forecast of $4.08 billion, according to FactSet. Research-and-development revenue rose 4.5% to $2.26 billion.IQVIA now anticipates 2025 adjusted earnings in a range between $11.85 and $11.95 a share, compared with a previous estimate of $11.75 to $12.05 a share.IQVIA now expects 2025 revenue of $16.15 billion to $16.25 billion.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","BK4588":"碎股","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","IQV":"艾昆纬","BK4121":"生命科学工具和服务","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4585":"ETF&股票定投概念","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","BK4530":"医药外包概念"},"translate_title":"Iqvia第三季度利润、营业额因需求增加而上升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IQV":1.5},"content_text":"By Rob Curran \n\n\n \n\n\n  Iqvia's third-quarter net income and revenue rose amid growing demand for its healthcare technology and research services. \n\n\n  The Research Triangle Park, N.C., firm, which conducts clinical trials for drug companies, among other services, on Tuesday posted third-quarter earnings of $331 million, or $1.93 a share, up from $285 million, or $1.55 a share, a year earlier. \n\n\n  Stripping out certain one-off items, IQVIA logged adjusted earnings of $3 a share, edging the average Wall Street estimate of $2.98 a share, as per FactSet. \n\n\n  Revenue rose 5.2% to $4.1 billion, about in line with the average analyst forecast of $4.08 billion, according to FactSet. Research-and-development revenue rose 4.5% to $2.26 billion. \n\n\n  IQVIA now anticipates 2025 adjusted earnings in a range between $11.85 and $11.95 a share, compared with a previous estimate of $11.75 to $12.05 a share. \n\n\n  IQVIA now expects 2025 revenue of $16.15 billion to $16.25 billion. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 28, 2025 07:50 ET (11:50 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}